AlphaMadera's AlphaVal page classifies IRadimed Corporation as a Platform & Compounding FCF business and values it using Two-stage FCF DCF, then compares the result to the current market price to flag IRMD as undervalued, fairly valued, or overvalued.

What is IRadimed Corporation's fair value?

Fair value for IRMD comes from a Two-stage FCF DCF model -- the approach AlphaVal selected for this company's Platform & Compounding FCF classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value IRMD?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. IRMD was classified as Platform & Compounding FCF and is valued using Two-stage FCF DCF, built from IRMD's most recent reported fundamentals.

IRMD - IRadimed Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $100.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 51.9% above fair value

Current Price $83.51

Bear Case $32.50 61.1% downside ($32.50 - $83.51) / $83.51 = -61.1% 12% stage 1 growth, 11% discount

Fair Value $54.98 34.2% downside ($54.98 - $83.51) / $83.51 = -34.2% 19% stage 1 growth, 11% discount

Bull Case $82.78 0.9% downside ($82.78 - $83.51) / $83.51 = -0.9% 25% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

19.3%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (19% base case)

Terminal Value % of EV 46%

Implied Market Multiple 67.8x

Market is pricing in (growth) 25.2% vs our 19.3% base

Plain-Language Summary

Using a two-stage FCF DCF with 19% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $54.98 per share.

Warnings

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions